ferabright®
ferumoxytol injection
Bright for
Brain Tumors
铁基造影剂
The first and only iron-based MRI contrast agent approved by FDA for brain imaging. Revolutionary ferumoxytol injection for visualizing blood-brain barrier disruption in malignant neoplasms.
MRI Compatible
Clinical Environment
Revolutionary Iron-Based Technology
ferabright® delivers superparamagnetic iron oxide nanoparticle enhanced imaging with superior advantages over traditional contrast agents
First Iron-Based Brain MRI Agent
Global breakthrough in brain tumor imaging technology, replacing traditional gadolinium-based agents with innovative iron nanoparticles.
Enhanced Blood-Brain Barrier Visualization
Superior detection of BBB disruption in gliomas, brain metastases, and micro lesions with unprecedented clarity.
Extended Imaging Window
Longer imaging duration enables delayed scanning, flexible protocols, and comprehensive sequence selection.
Safe for Renal Impaired Patients
Alternative solution for patients with kidney dysfunction who cannot receive gadolinium-based agents.
Natural Iron Metabolism
Eliminated through body's natural iron pathways, reducing concerns about long-term heavy metal accumulation.
Superior Contrast Performance
High relaxivity superparamagnetic properties provide exceptional contrast enhancement and diagnostic precision.
See ferabright® In Action
Watch how this revolutionary iron-based MRI contrast agent is transforming brain tumor imaging and patient care
Revolutionary Iron-Based Brain Imaging
Discover how ferabright® is setting new standards in brain MRI contrast enhancement with superior safety and efficacy profiles.